Use your antibodies-online credentials, if available.
抗Human HIC1 抗体:
抗Mouse (Murine) HIC1 抗体:
抗Rat (Rattus) HIC1 抗体:
Cow (Bovine) Polyclonal HIC1 Primary Antibody for WB - ABIN2780783
Stöcklein, Smardova, Macak, Katzenberger, Höller, Wessendorf, Hutter, Dreyling, Haralambieva, Mäder, Müller-Hermelink, Rosenwald, Ott, Kalla: Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma. in Oncogene 2008
Human Polyclonal HIC1 Primary Antibody for ELISA, WB - ABIN4317303
Yu, Liu, Cui, Sui, Ji, Guan, Sun, Ji, Liu, Liu, Zhao, Yu, Jin, Bai, Geng, Xue, Qi, Lee, Fu: Identification of novel subregions of LOH in gastric cancer and analysis of the HIC1 and TOB1 tumor suppressor genes in these subregions. in Molecules and cells 2011
These results suggest that up-regulation of MVP in multi-drug resistance (MDR) may involve chromatin remodeling.
In this present work, the authors identify and characterize a transcription factor i.e. HIC1, which physically interacts with both Bcl11b/CTIP2 and HMGA1 to co-regulate specific subsets of cellular genes and the HIV-1 tat gene.
our data demonstrate that HIC1 SUMOylation is important for the transcriptional response to non-repairable DSBs but dispensable for DNA repair.
Data suggest that aberrant expression of hypermethylated in cancer-1 (HIC1)/sirtuin-1 (SIRT1) and hypermethylation of the HIC1 promoter may be critical for the development and progression of papillary thyroid cancer.
Hypermethylation of HIC1 gene is associated with Colon Cancer.
Data show that secretion of IL-6 induced by loss of HIC1 activated STAT3 through IL-6/JAK pathway and was associated with NSCLC progression.
The VNTR sequence near HIC1 could be a predictive marker for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Therefore, our data identify HIC1 as a novel factor involved in B cell differentiation acting as an epigenetic repressor of CIITA transcription.
HIC1 loss promotes prostate cancer metastasis by triggering epithelial-mesenchymal transition.
Data show that expression of hypermethylated in cancer 1 protein (HIC1) is downregulated in uveal melanoma.
HIC1 attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic ductal adenocarcinoma.
Epigenetic silencing of HIC1 promotes epithelial-mesenchymal transition and drives progression in esophageal squamous cell carcinoma via EphA2 signaling.
The tumor-suppressive function of Hic1 in colon is related to its inhibitory action on proproliferative signaling mediated by the Tlr2 receptor present on tumor cells.
Results demonstrated an important role of HIC1 for the normal progression of cell cycle, and could affect the homeostasis of p53 as well as number of cell cycle-related genes, which may or may not be directly linked to p53.
We found that EVI1 and HIC1 colocalize in the nucleus, and their interaction is mediated by the amino terminal zinc finger binding domain of EVI1
HIC-1 expression was assessed on a tissue microarray containing 80 cases of breast cancer.
Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer.
ectopic expression of HIC1 in U2OS and MDA-MB-231 cell lines decreases expression of the ApoER2 and VLDLR genes, encoding two canonical tyrosine kinase receptors for Reelin.
HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.
HIC1 interacts with and modulates the transcriptional activity of STAT3.
Reactivation of HIC1 suppressed cell migration and induced cell cycle arrest in the G0/G1 phase, as well as induced apoptosis in gastric cancer cells.
Intestinal innate lymphoid cells express HIC1 in a vitamin A-dependent manner.
this study identified a critical role for HIC1 in the regulation of T-cell function in the intestinal microenvironment under both homeostatic and inflammatory conditions
identify HIC1 as the first transcription factor in mammals able to recruit PRC2 to some target promoters through its interaction with Polycomb-like proteins.
Data show that Hic1 expression is absent in polyps from DH mice, with concomitant increased expression of two transcriptional repression targets of Hic1, Sirt1 and Sox9.
A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1.
mice disrupted in the germ line for only one allele of Hic1 develop many different spontaneous malignant tumors, including a predominance of epithelial cancers in males and lymphomas and sarcomas in females
In human osteosarcomas, hypermethylation of HIC1 is frequent only in tumors with p53 mutation
Inactivation of HIC1 results in upregulated SIRT1 expression in normal or cancer cells; this deacetylates and inactivates p53, allowing cells to bypass apoptosis and survive DNA damage.
For the Hic-1 gene, but not p16, the p53 gene might protect against aberrant methylation. The iNOS gene might not be involved in methylation of the Hic-1 gene, whereas the promoter region of p16 could be prone to methylation in MEFs lacking the iNOS gene.
This gene functions as a growth regulatory and tumor repressor gene. Hypermethylation or deletion of the region of this gene have been associated with tumors and the contiguous-gene syndrome, Miller-Dieker syndrome. Alternative splicing of this gene results in multiple transcript variants.
, hypermethylated in cancer 1 protein
, hypermethylated in cancer 1
, zinc finger and BTB domain-containing protein 29
, hypermethylated in cancer 1 protein-like